Zealand Pharma A/S
ZEAL
Kedudukan dalam Saham
#5483
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Harga Saham
$35.84
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$2.49B
Perubahan (1 hari)
-1.27%
Perubahan (1 tahun)
-49.95%
Negara
DK
Perdagangan Zealand Pharma A/S (ZEAL)
Kategori
Healthcare
Modal pasaran bagi Zealand Pharma A/S(ZEAL)
Modal Pasaran: $2.49B
Sehingga October 2026, Zealand Pharma A/S mempunyai modal pasaran sebanyak $2.49B. Ini menjadikan Zealand Pharma A/S syarikat ke-5483rd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Zealand Pharma A/S dari 2013 hingga 2026
ZEAL berbanding dengan 5 teratas yang paling popular stocks
